China Health Group Full Year 2024 Earnings: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group (HKG:673) Full Year 2024 Results

Key Financial Results

• Revenue: HK$59.9m (down 22% from FY 2023).
• Net loss: HK$40.2m (loss narrowed by 4.4% from FY 2023).
• HK$0.085 loss per share (improved from HK$0.099 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Distribution and Service in Medical Equipment and Consumables segment contributing a total revenue of HK$45.8m (77% of total revenue). Notably, cost of sales worth HK$46.3m amounted to 77% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to HK$32.0m (59% of total expenses). Explore how 673's revenue and expenses shape its earnings.

China Health Group shares are down 9.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for China Health Group (1 doesn't sit too well with us!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com